Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
View Patent ↗A mixture of conjugates in which each conjugate in the mixture comprises a calcitonin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may lower serum calcium levels in a subject by 10, 15 or even 20 percent or more. Moreover, the mixture may be more effective at surviving an in vitro model of intestinal digestion than non-conjugated calcitonin. Furthermore, the mixture may exhibit a higher bioavailability than non-conjugated calcitonin.
1. A mixture of conjugates, wherein each conjugate consists of a calcitonin and a polyethylene glycol moiety, wherein the polyethylene glycol moiety is coupled to an amine function of the calcitonin, wherein the mixture is a monodispersed mixture, a substantially purely monodispersed mixture or a purely monodispersed mixture.
2. The mixture according to claim 1 , wherein the polyethylene glycol moiety has at least 2 polyethylene glycol subunits.
3. The mixture according to claim 1 , wherein the conjugates have the capability of lowering serum calcium levels by at least 5 percent.
4. The mixture according to claim 1 , wherein the conjugates have an increased resistance to degradation by chymotrypsin or trypsin when compared to the resistance to degradation by chymotrypsin or trypsin of the calcitonin which is not coupled to the polyethylene glycol moiety.
5. The mixture according to claim 1 , wherein the conjugates have a bioefficacy that is greater than the bioefficacy of the calcitonin which is not coupled to the oligomer.
6. The mixture according to claim 1 , wherein the calcitonin is covalently coupled to the polyethylene glycol moiety by a hydrolyzable bond, a non-hydrolyzable bond or both.
7. The mixture according to claim 1 , wherein the calcitonin is covalently coupled to the polyethylene glycol moiety.
8. The mixture according to claim 1 , wherein each the polyethylene glycol moiety has the same molecular structure.
9. The mixture according to claim 1 , wherein the conjugates are each amphihically balanced such that each conjugate is aqueously soluble to penetrate biological membranes.
10. A composition comprising:
the mixture according to claim 1 ; and
a pharmaceutically acceptable carrier.
11. A method of treating a bone disorder in a subject in need of such treatment, said method comprising administering an effective amount of a mixture of conjugates according to claim 1 to the subject to treat the bone disorder.
12. The method according to claim 11 , wherein the bone disorder is osteoporosis Paget's disease, or hypercalcemia.
13. A monodispersed mixture of conjugates, wherein each conjugate consists of a calcitonin coupled to at least one polyethylene glycol moiety consisting of at least 4 polyethylene glycol subunits, wherein coupling between the calcitonin and the polyethylene glycol moiety-consists of an amine bond(s), said mixture having a molecular weight distribution with a standard deviation of less than about 22 Daltons.
14. A mixture of conjugates wherein each conjugate consists of a calcitonin coupled to at least one polyethylene glycol moiety, wherein coupling between the calcitonin and the polyethylene glycol moiety consists of an amine bond(s), wherein the mixture has a dispersity coefficient (DC) greater than 10,000 where
DC
=
(
∑
i
=
1
n
N
i
M
i
)
2
∑
i
=
1
n
N
i
M
i
2
∑
i
=
1
n
N
i
-
(
∑
i
=
1
n
N
i
M
i
)
2
wherein:
n is the number of different molecules in the sample;
N i is the number of i th molecules in the sample; and
M i is the mass of the i th molecule.
15. The mixture of conjugates according to claim 14 , wherein the dispersity coefficient is greater than 100,000.